Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00940225 · OUTCOME

Bone Scan Response (BSR) - NRE, CRPC

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies · Source last updated 2024-04-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
From initial dose through final study visit up to 15 months

What was measured

The reduction of bone scan lesion area (BSLA) by \> 30% was used as the quantitative measure of BSR. BSR was a primary outcome measure for only the NRE CRPC Cohorts.

Groups in this outcome

NRE Cohort - CRPC 100 mg

cabozantinib, 100 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.

NRE Cohort - CRPC 39.4 mg

cabozantinib, 39.4 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
NRE Cohort - CRPC 100 mg93
NRE Cohort - CRPC 39.4 mg51

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
NRE Cohort - CRPC 100 mg74.2Not reported64.182.7Not reported
NRE Cohort - CRPC 39.4 mg47.1Not reported32.961.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        64.1
        upper Limit
        82.7
        value
        74.2
      2. group Id
        OG001
        lower Limit
        32.9
        upper Limit
        61.5
        value
        47.1
denoms
  1. counts
    1. group Id
      OG000
      value
      93
    2. group Id
      OG001
      value
      51
    units
    Participants
description
The reduction of bone scan lesion area (BSLA) by \> 30% was used as the quantitative measure of BSR. BSR was a primary outcome measure for only the NRE CRPC Cohorts.
dispersion Type
95% Confidence Interval
groups
  1. description
    cabozantinib, 100 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.
    id
    OG000
    title
    NRE Cohort - CRPC 100 mg
  2. description
    cabozantinib, 39.4 milligrams orally, daily for 12 weeks until progression or unacceptable toxicity.
    id
    OG001
    title
    NRE Cohort - CRPC 39.4 mg
param Type
NUMBER
reporting Status
POSTED
time Frame
From initial dose through final study visit up to 15 months
title
Bone Scan Response (BSR) - NRE, CRPC
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice